Evidence map›Paper›PMID 33414172›Full record

ArticleCancer research2021

Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth.

Shinji Iizuka, Manuela Quintavalle, Jose C Navarro, Kyle P Gribbin, Robert J Ardecky, Matthew M Abelman, Chen-Ting Ma, Eduard Sergienko, Fu-Yue Zeng, Ian Pass and 5 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. The role of TAOK3 in cancer progression and development as a prognostic marker: A pan-cancer analysis study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Tissue remodeling by invadosomes.Faculty reviews · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Shinji Iizuka *Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Manuela Quintavalle *Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Jose C NavarroDepartment of Cell Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Kyle P GribbinDepartment of Cell Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Robert J ArdeckySanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Matthew M AbelmanSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Chen-Ting MaSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Eduard SergienkoSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Fu-Yue ZengSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Ian PassSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
George V ThomasKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Christian A HassigSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Anthony B PinkertonSanford Burnham Prebys Medical Discovery Institute, La Jolla, California.ORCID 0000-0003-4571-152X
Sara A CourtneidgeSanford Burnham Prebys Medical Discovery Institute, La Jolla, California. courtneidge@ohsu.edu.
Discovery Institute · USOregon Health & Science University · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Proteomics CoreP30EY010572 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI John Peter Campbell · 1995 to 2026
$19.4M
Validating and Characterizing a New Melanoma Therapeutic TargetR01CA217625 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI COURTNEIDGE, SARA A · 2017 to 2020
$2.5M
Kinases as therapeutic targets for cancer progressionR01CA154002 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COURTNEIDGE, SARA A · 2011 to 2015
$1.9M
Inhibiting VHL-positive kidney cancerR01CA169172 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI THOMAS, GEORGE VICTOR · 2013 to 2017
$1.6M
LTQ Orbitrap VelosS10OD012246 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI DAVID, LARRY L · 2012 to 2012
$854k
NCI NIH HHS P30 CA030199NCI NIH HHS P30 CA069533NCI NIH HHS R01 CA154002NCI NIH HHS R01 CA169172NCI NIH HHS R01 CA217625NEI NIH HHS P30 EY010572NIH HHS S10 OD012246
6 · The paper itself

Abstract

Invadopodia are actin-based proteolytic membrane protrusions required for invasive behavior and tumor growth. In this study, we used our high-content screening assay to identify kinases whose activity affects invadopodia formation. Among the top hits selected for further analysis was TAO3, an STE20-like kinase of the GCK subfamily. TAO3 was overexpressed in many human cancers and regulated invadopodia formation in melanoma, breast, and bladder cancers. Furthermore, TAO3 catalytic activity facilitated melanoma growth in three-dimensional matrices and

Indexed as

Adaptor Proteins, Vesicular TransportAnimalsAntineoplastic AgentsCell Line, TumorCytoplasmic DyneinsDatasets as TopicEndosomesExtracellular MatrixFemaleGene Expression ProfilingGene Knockdown TechniquesHigh-Throughput Screening AssaysHumansMaleMelanomaMiceAdaptor Proteins, Vesicular TransportAntineoplastic AgentsCytoplasmic DyneinsDYNC1LI2 protein, humanProtein Serine-Threonine KinasesSH3PXD2A protein, humanTAOK3 protein, human

Identifiers

PMID33414172
PMCPMC7969469
OpenAlexW3118295684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.